SCHEMBL25366978

SCHEMBL25366978

Nc1cc(C(=O)O)ccc1NCC1CCO1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HCAR3 P49019 2/20 0.59
▸ GAA P10253 8/20 0.57
▸ ALDH1A1 P00352 8/20 0.57
▸ KDM4E B2RXH2 7/20 0.57
▸ MAPT P10636 6/20 0.57
▸ GFER P55789 4/20 0.57
▸ THRB P10828 3/20 0.57
▸ HPGD P15428 3/20 0.57
▸ HTT P42858 2/20 0.57
▸ PLEC Q15149 1/20 0.57
▸ PTGER4 P35408 2/20 0.51
▸ HSD17B10 Q99714 4/20 0.50
▸ KMT2A Q03164 3/20 0.49
▸ SMN1; SMN2 Q16637 4/20 0.47
▸ RAB9A P51151 3/20 0.47
▸ NPC1 O15118 4/20 0.47
▸ L3MBTL1 Q9Y468 3/20 0.47
▸ GLA P06280 1/20 0.47
▸ RCE1 Q9Y256 1/20 0.47
▸ TSHR P16473 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25366974 1.00 HCAR3 (0.59) HCAR3GAAALDH1A1KDM4EMAPT
SCHEMBL20266401 0.89 HCAR3 (0.56) HCAR3GAAALDH1A1KDM4EMAPT
SCHEMBL20266402 0.89 HCAR3 (0.56) HCAR3GAAALDH1A1KDM4EMAPT
SCHEMBL17938336 0.87 GAA (0.52) HCAR3GAAALDH1A1KDM4EMAPT
SCHEMBL29052950 0.86 PTGER4 (0.58) HCAR3GAAALDH1A1KDM4EMAPT
SCHEMBL24306327 0.86 PTGER4 (0.58) HCAR3GAAALDH1A1KDM4EMAPT
SCHEMBL30537054 0.86 PTGER4 (0.58) HCAR3GAAALDH1A1KDM4EMAPT
SCHEMBL29001666 0.83 HCAR3 (0.61) HCAR3ALDH1A1KDM4EMAPTHPGD
SCHEMBL28939260 0.83 HCAR3 (0.65) HCAR3ALDH1A1KDM4EMAPTHPGD
SCHEMBL29001669 0.83 HCAR3 (0.61) HCAR3ALDH1A1KDM4EMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240083886-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2024-03-14 — — US disclosed
US-20230391760-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2023-12-07 — — US disclosed
WO-2023164358-A1 GLP-1R MODULATING COMPOUNDS ASCLETIS BIOSCIENCE CO., LTD. (CN) 2023-08-31 — — WO disclosed
US-20230271949-A1 GLP-1R MODULATING COMPOUNDS ASCLETIS BIOSCIENCE CO., LTD. (CN) 2023-08-31 — — US disclosed
CN-116547278-A Heterocyclic GLP-1 agonists 加舒布鲁姆生物公司 2023-08-04 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230391760-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR HCAR3 393/4885GAA 1083/4885ALDH1A1 840/4885
US-20230271949-A1 GLP-1R MODULATING COMPOUNDS GLP1R, GIPR, GPR119 HCAR3 230/4885GAA 2185/4885ALDH1A1 3386/4885
US-20240083886-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR HCAR3 310/4885GAA 1394/4885ALDH1A1 1011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback